Investment analysts at StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “buy” rating on the stock.
A number of other equities research analysts also recently commented on the stock. Brookline Capital Management downgraded shares of MEI Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, July 22nd. Laidlaw lowered shares of MEI Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $7.00.
Check Out Our Latest Analysis on MEI Pharma
MEI Pharma Stock Performance
MEI Pharma (NASDAQ:MEIP – Get Free Report) last posted its quarterly earnings data on Thursday, September 19th. The company reported ($1.13) EPS for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.35. On average, analysts forecast that MEI Pharma will post -5.1 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in MEI Pharma stock. Cable Car Capital LLC bought a new stake in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 611,440 shares of the company’s stock, valued at approximately $3,546,000. MEI Pharma comprises about 3.9% of Cable Car Capital LLC’s portfolio, making the stock its 10th biggest holding. Cable Car Capital LLC owned 9.18% of MEI Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 52.38% of the company’s stock.
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Stories
- Five stocks we like better than MEI Pharma
- How Investors Can Find the Best Cheap Dividend Stocks
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Stock Market Upgrades: What Are They?
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Consumer Staples Stocks, Explained
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.